2-chloro-4-((7S,7aR)-7-hydroxy-1-methyl-3-oxo-5,6,7,7a-tetrahydro-3H-pyrrolizin-2-yl)-3-methylbenzonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯嗪
• 英文名称: 2-chloro-4-((7S,7aR)-7-hydroxy-1-methyl-3-oxo-5,6,7,7a-tetrahydro-3H-pyrrolizin-2-yl)-3-methylbenzonitrile
• 英文别名: Pyrrol-2-one, 14；2-chloro-4-[(7S,8R)-7-hydroxy-1-methyl-3-oxo-5,6,7,8-tetrahydropyrrolizin-2-yl]-3-methylbenzonitrile
• 化学式: C₁₆H₁₅ClN₂O₂
• 分子量: 302.76
• InChiKey: NEHDVDXRTNOXMK-SWLSCSKDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  64.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(4-溴-3-氯-2-甲基苯基)乙酰胺 在 哌啶 、 盐酸 、 sodium hydroxide 、 copper(l) iodide 、 亚硝酸特丁酯 、 乙醇 、 sodium hydride 、 氟化氢吡啶 、 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 127.0h， 生成 2-chloro-4-((7S,7aR)-7-hydroxy-1-methyl-3-oxo-5,6,7,7a-tetrahydro-3H-pyrrolizin-2-yl)-3-methylbenzonitrile
  参考文献：
  名称：

  Discovery of Potent and Muscle Selective Androgen Receptor Modulators through Scaffold Modifications

  摘要：

  A novel series of imidazolin-2-ones were designed and synthesized as highly potent, orally active and muscle selective androgen receptor modulators (SARMs), with most of the compounds exhibiting low nM in vitro potency in androgen receptor (AR) binding and functional assays. Once daily oral treatment with the lead compound 11a (AR K-i = 0.9 nM, EC50 = 1.8 nM) for 14 days induced muscle growth with an ED50 of 0.09 mg/kg, providing approximately 50-fold selectivity over prostate growth in an orchidectomized rat model. Pharmacokinetic studies in rats demonstrated that the lead compound 11a had oral bioavailability of 65% and a plasma half-life of 5.5 h. On the basis of their preclinical profiles, the SARMs in this series are expected to provide beneficial anabolic effects on muscle with minimal androgenic effects on prostate tissue.

  DOI：

  10.1021/jm070312d

文献信息

• Novel bicyclic compounds as modulators of androgen receptor function and method
  申请人：Li J. James

  公开号：US20050197367A1

  公开（公告）日：2005-09-08

  The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R 1 , R 2 , R 2′ R 5 , G, n and W are defined herein.

  本发明涉及符合式I的双环化合物，包含这种化合物的药物组合物以及使用这种化合物治疗与雄激素受体相关的疾病的方法，例如与年龄相关的疾病，例如肌少症，其中R1、R2、R2′、R5、G、n和W在此处定义。
• NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION
  申请人：LI J. James

  公开号：US20080103188A1

  公开（公告）日：2008-05-01

  There are provided bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R 1 , R 2 , R 2 ′, R 5 , G, n and W are defined herein. Other embodiments are also provided.

  提供了根据公式I的双环化合物、含有这种化合物的药物组合物以及使用这种化合物治疗与雄激素受体相关的疾病的方法，例如与年龄相关的疾病，例如肌肉萎缩症，其中R1、R2、R2'、R5、G、n和W在此定义。还提供了其他实施方式。
• US7388027B2
  申请人：——

  公开号：US7388027B2

  公开（公告）日：2008-06-17
• Discovery of Potent and Muscle Selective Androgen Receptor Modulators through Scaffold Modifications
  作者：James J. Li、James C. Sutton、Alexandra Nirschl、Yan Zou、Haixia Wang、Chongqing Sun、Zulan Pi、Rebecca Johnson、Stanley R. Krystek,、Ramakrishna Seethala、Rajasree Golla、Paul G. Sleph、Blake C. Beehler、Gary J. Grover、Aberra Fura、Viral P. Vyas、Cindy Y. Li、Jack Z. Gougoutas、Michael A. Galella、Robert Zahler、Jacek Ostrowski、Lawrence G. Hamann

  DOI：10.1021/jm070312d

  日期：2007.6.1

  A novel series of imidazolin-2-ones were designed and synthesized as highly potent, orally active and muscle selective androgen receptor modulators (SARMs), with most of the compounds exhibiting low nM in vitro potency in androgen receptor (AR) binding and functional assays. Once daily oral treatment with the lead compound 11a (AR K-i = 0.9 nM, EC50 = 1.8 nM) for 14 days induced muscle growth with an ED50 of 0.09 mg/kg, providing approximately 50-fold selectivity over prostate growth in an orchidectomized rat model. Pharmacokinetic studies in rats demonstrated that the lead compound 11a had oral bioavailability of 65% and a plasma half-life of 5.5 h. On the basis of their preclinical profiles, the SARMs in this series are expected to provide beneficial anabolic effects on muscle with minimal androgenic effects on prostate tissue.